Alexandre Aubourg

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Geert D’Haens, Séverine Vermeire, Guy Lambrecht et al. · Gastroenterology · 2018 · 299 citations · Full text

Veterinary Medicine, Clinical Sciences, Pharmacotherapy +12

Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

David Ternant, Alexandre Aubourg, Charlotte Magdelaine–Beuzelin et al. · Therapeutic Drug Monitoring · 2008 · 181 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Aurélien Amiot, Mélanie Serrero, Laurent Peyrin‐Biroulet et al. · Alimentary Pharmacology & Therapeutics · 2017 · 177 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <scp>OBSERV</scp>‐<scp>IBD</scp> cohort

S. Tadbiri, Laurent Peyrin‐Biroulet, Mélanie Serrero et al. · Alimentary Pharmacology & Therapeutics · 2017 · 112 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort

Yaël Abitbol, David Laharie, Jacques Cosnes et al. · Journal of Crohn s and Colitis · 2016 · 69 citations

Medicine, Infectious Diseases, Internal Medicine +16